APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neutrophil Elastase Inhibitator

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Neutrophil Elastase Inhibitator Industry Growth and Trends Forecast to 2032

Report ID 174016740119 December 202591 pages

Choose your research edition.

Industry ResearchNeutrophil Elastase Inhibitator Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Neutrophil Elastase Inhibitator Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Neutrophil Elastase Inhibitator Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neutrophil Elastase Inhibitator Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Neutrophil Elastase Inhibitator Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Neutrophil Elastase Inhibitator market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Neutrophil Elastase Inhibitator is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Neutrophil Elastase Inhibitator is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neutrophil Elastase Inhibitator is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neutrophil Elastase Inhibitator include AstraZeneca Plc, Polyphor Ltd, Kyorin Pharmaceutical Co Ltd, Chiesi Farmaceutici SpA and Cantex Pharmaceuticals Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Neutrophil Elastase Inhibitator market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Neutrophil Elastase Inhibitator market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Neutrophil Elastase Inhibitator market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Neutrophil Elastase Inhibitator.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Neutrophil Elastase Inhibitator market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Neutrophil Elastase Inhibitator Market by Company

AstraZeneca Plc

Polyphor Ltd

Kyorin Pharmaceutical Co Ltd

Chiesi Farmaceutici SpA

Cantex Pharmaceuticals Inc

Neutrophil Elastase Inhibitator Segment by Type

Dociparstat Sodium

POL-6014

KRP-109

CHF-6333

Brevenal

Others

Neutrophil Elastase Inhibitator Segment by Application

Bronchiectasis

Acute Myelocytic Leukemia

Respiratory

Others

Neutrophil Elastase Inhibitator Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neutrophil Elastase Inhibitator market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neutrophil Elastase Inhibitator and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neutrophil Elastase Inhibitator.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Neutrophil Elastase Inhibitator manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Neutrophil Elastase Inhibitator in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Dociparstat Sodium Table 2. Major Company of POL-6014 Table 3. Major Company of KRP-109 Table 4. Major Company of CHF-6333 Table 5. Major Company of Brevenal Table 6. Major Company of Others Table 7. Global Neutrophil Elastase Inhibitator Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Neutrophil Elastase Inhibitator Sales by Type (2021-2026) & (W Units) Table 9. Global Neutrophil Elastase Inhibitator Sales Market Share in Volume by Type (2021-2026) Table 10. Global Neutrophil Elastase Inhibitator Sales by Type (2021-2026) & (US$ Million) Table 11. Global Neutrophil Elastase Inhibitator Sales Market Share in Value by Type (2021-2026) Table 12. Global Neutrophil Elastase Inhibitator Price by Type (2021-2026) & (US$/Unit) Table 13. Global Neutrophil Elastase Inhibitator Sales by Type (2027-2032) & (W Units) Table 14. Global Neutrophil Elastase Inhibitator Sales Market Share in Volume by Type (2027-2032) Table 15. Global Neutrophil Elastase Inhibitator Sales by Type (2027-2032) & (US$ Million) Table 16. Global Neutrophil Elastase Inhibitator Sales Market Share in Value by Type (2027-2032) Table 17. Global Neutrophil Elastase Inhibitator Price by Type (2027-2032) & (US$/Unit) Table 18. North America Neutrophil Elastase Inhibitator Sales by Type (2021-2026) & (W Units) Table 19. North America Neutrophil Elastase Inhibitator Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Neutrophil Elastase Inhibitator Sales by Type (2021-2026) & (W Units) Table 21. Europe Neutrophil Elastase Inhibitator Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Neutrophil Elastase Inhibitator Sales by Type (2021-2026) & (W Units) Table 23. Asia-Pacific Neutrophil Elastase Inhibitator Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Neutrophil Elastase Inhibitator Sales by Type (2021-2026) & (W Units) Table 25. Latin America Neutrophil Elastase Inhibitator Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Neutrophil Elastase Inhibitator Sales by Type (2021-2026) & (W Units) Table 27. Middle East and Africa Neutrophil Elastase Inhibitator Sales by Type (2021-2026) & (US$ Million) Table 28. Neutrophil Elastase Inhibitator Industry Trends Table 29. Neutrophil Elastase Inhibitator Industry Drivers Table 30. Neutrophil Elastase Inhibitator Industry Opportunities and Challenges Table 31. Neutrophil Elastase Inhibitator Industry Restraints Table 32. Global Neutrophil Elastase Inhibitator Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Neutrophil Elastase Inhibitator Revenue Market Share by Company (2021-2026) Table 34. Global Neutrophil Elastase Inhibitator Sales by Company (2021-2026) & (W Units) Table 35. Global Neutrophil Elastase Inhibitator Sales Share by Company (2021-2026) Table 36. Global Neutrophil Elastase Inhibitator Market Price by Company (2021-2026) & (US$/Unit) Table 37. Global Neutrophil Elastase Inhibitator Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Neutrophil Elastase Inhibitator Major Company Production Sites and Headquarters Table 39. Global Neutrophil Elastase Inhibitator Company, Product Type & Application Table 40. Global Neutrophil Elastase Inhibitator Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Neutrophil Elastase Inhibitator by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Neutrophil Elastase Inhibitator Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Neutrophil Elastase Inhibitator Sales by Region (2021-2026) & (W Units) Table 45. Global Neutrophil Elastase Inhibitator Sales Market Share in Volume by Region (2021-2026) Table 46. Global Neutrophil Elastase Inhibitator Sales by Region (2021-2026) & (US$ Million) Table 47. Global Neutrophil Elastase Inhibitator Sales Market Share in Value by Region (2021-2026) Table 48. Global Neutrophil Elastase Inhibitator Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 49. Global Neutrophil Elastase Inhibitator Sales by Region (2027-2032) & (W Units) Table 50. Global Neutrophil Elastase Inhibitator Sales Market Share in Volume by Region (2027-2032) Table 51. Global Neutrophil Elastase Inhibitator Sales by Region (2027-2032) & (US$ Million) Table 52. Global Neutrophil Elastase Inhibitator Sales Market Share in Value by Region (2027-2032) Table 53. Global Neutrophil Elastase Inhibitator Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 54. Global Neutrophil Elastase Inhibitator Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Neutrophil Elastase Inhibitator Sales by Application (2021-2026) & (W Units) Table 56. Global Neutrophil Elastase Inhibitator Sales Market Share in Volume by Application (2021-2026) Table 57. Global Neutrophil Elastase Inhibitator Sales by Application (2021-2026) & (US$ Million) Table 58. Global Neutrophil Elastase Inhibitator Sales Market Share in Value by Application (2021-2026) Table 59. Global Neutrophil Elastase Inhibitator Price by Application (2021-2026) & (US$/Unit) Table 60. Global Neutrophil Elastase Inhibitator Sales by Application (2027-2032) & (W Units) Table 61. Global Neutrophil Elastase Inhibitator Sales Market Share in Volume by Application (2027-2032) Table 62. Global Neutrophil Elastase Inhibitator Sales by Application (2027-2032) & (US$ Million) Table 63. Global Neutrophil Elastase Inhibitator Sales Market Share in Value by Application (2027-2032) Table 64. Global Neutrophil Elastase Inhibitator Price by Application (2027-2032) & (US$/Unit) Table 65. North America Neutrophil Elastase Inhibitator Sales by Application (2021-2026) & (W Units) Table 66. North America Neutrophil Elastase Inhibitator Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Neutrophil Elastase Inhibitator Sales by Application (2021-2026) & (W Units) Table 68. Europe Neutrophil Elastase Inhibitator Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Neutrophil Elastase Inhibitator Sales by Application (2021-2026) & (W Units) Table 70. Asia-Pacific Neutrophil Elastase Inhibitator Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Neutrophil Elastase Inhibitator Sales by Application (2021-2026) & (W Units) Table 72. Latin America Neutrophil Elastase Inhibitator Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Neutrophil Elastase Inhibitator Sales by Application (2021-2026) & (W Units) Table 74. Middle East and Africa Neutrophil Elastase Inhibitator Sales by Application (2021-2026) & (US$ Million) Table 75. AstraZeneca Plc Company Information Table 76. AstraZeneca Plc Business Overview Table 77. AstraZeneca Plc Neutrophil Elastase Inhibitator Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. AstraZeneca Plc Neutrophil Elastase Inhibitator Product Portfolio Table 79. AstraZeneca Plc Recent Development Table 80. Polyphor Ltd Company Information Table 81. Polyphor Ltd Business Overview Table 82. Polyphor Ltd Neutrophil Elastase Inhibitator Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Polyphor Ltd Neutrophil Elastase Inhibitator Product Portfolio Table 84. Polyphor Ltd Recent Development Table 85. Kyorin Pharmaceutical Co Ltd Company Information Table 86. Kyorin Pharmaceutical Co Ltd Business Overview Table 87. Kyorin Pharmaceutical Co Ltd Neutrophil Elastase Inhibitator Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Kyorin Pharmaceutical Co Ltd Neutrophil Elastase Inhibitator Product Portfolio Table 89. Kyorin Pharmaceutical Co Ltd Recent Development Table 90. Chiesi Farmaceutici SpA Company Information Table 91. Chiesi Farmaceutici SpA Business Overview Table 92. Chiesi Farmaceutici SpA Neutrophil Elastase Inhibitator Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Chiesi Farmaceutici SpA Neutrophil Elastase Inhibitator Product Portfolio Table 94. Chiesi Farmaceutici SpA Recent Development Table 95. Cantex Pharmaceuticals Inc Company Information Table 96. Cantex Pharmaceuticals Inc Business Overview Table 97. Cantex Pharmaceuticals Inc Neutrophil Elastase Inhibitator Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Cantex Pharmaceuticals Inc Neutrophil Elastase Inhibitator Product Portfolio Table 99. Cantex Pharmaceuticals Inc Recent Development Table 100. North America Neutrophil Elastase Inhibitator Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 101. North America Neutrophil Elastase Inhibitator Sales by Country (2021-2026) & (W Units) Table 102. North America Neutrophil Elastase Inhibitator Sales Market Share by Country (2021-2026) Table 103. North America Neutrophil Elastase Inhibitator Sales Forecast by Country (2027-2032) & (W Units) Table 104. North America Neutrophil Elastase Inhibitator Sales Market Share Forecast by Country (2027-2032) Table 105. North America Neutrophil Elastase Inhibitator Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 106. North America Neutrophil Elastase Inhibitator Market Size by Country (2021-2026) & (US$ Million) Table 107. North America Neutrophil Elastase Inhibitator Market Share by Country (2021-2026) Table 108. North America Neutrophil Elastase Inhibitator Market Size Forecast by Country (2027-2032) & (US$ Million) Table 109. North America Neutrophil Elastase Inhibitator Market Share Forecast by Country (2027-2032) Table 110. Europe Neutrophil Elastase Inhibitator Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 111. Europe Neutrophil Elastase Inhibitator Sales by Country (2021-2026) & (W Units) Table 112. Europe Neutrophil Elastase Inhibitator Sales Market Share by Country (2021-2026) Table 113. Europe Neutrophil Elastase Inhibitator Sales Forecast by Country (2027-2032) & (W Units) Table 114. Europe Neutrophil Elastase Inhibitator Sales Market Share Forecast by Country (2027-2032) Table 115. Europe Neutrophil Elastase Inhibitator Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 116. Europe Neutrophil Elastase Inhibitator Market Size by Country (2021-2026) & (US$ Million) Table 117. Europe Neutrophil Elastase Inhibitator Market Share by Country (2021-2026) Table 118. Europe Neutrophil Elastase Inhibitator Market Size Forecast by Country (2027-2032) & (US$ Million) Table 119. Europe Neutrophil Elastase Inhibitator Market Share Forecast by Country (2027-2032) Table 120. Asia-Pacific Neutrophil Elastase Inhibitator Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 121. Asia-Pacific Neutrophil Elastase Inhibitator Sales by Country (2021-2026) & (W Units) Table 122. Asia-Pacific Neutrophil Elastase Inhibitator Sales Market Share by Country (2021-2026) Table 123. Asia-Pacific Neutrophil Elastase Inhibitator Sales Forecast by Country (2027-2032) & (W Units) Table 124. Asia-Pacific Neutrophil Elastase Inhibitator Sales Market Share Forecast by Country (2027-2032) Table 125. Asia-Pacific Neutrophil Elastase Inhibitator Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 126. Asia-Pacific Neutrophil Elastase Inhibitator Market Size by Country (2021-2026) & (US$ Million) Table 127. Asia-Pacific Neutrophil Elastase Inhibitator Market Share by Country (2021-2026) Table 128. Asia-Pacific Neutrophil Elastase Inhibitator Market Size Forecast by Country (2027-2032) & (US$ Million) Table 129. Asia-Pacific Neutrophil Elastase Inhibitator Market Share Forecast by Country (2027-2032) Table 130. Latin America Neutrophil Elastase Inhibitator Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 131. Latin America Neutrophil Elastase Inhibitator Sales by Country (2021-2026) & (W Units) Table 132. Latin America Neutrophil Elastase Inhibitator Sales Market Share by Country (2021-2026) Table 133. Latin America Neutrophil Elastase Inhibitator Sales Forecast by Country (2027-2032) & (W Units) Table 134. Latin America Neutrophil Elastase Inhibitator Sales Market Share Forecast by Country (2027-2032) Table 135. Latin America Neutrophil Elastase Inhibitator Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 136. Latin America Neutrophil Elastase Inhibitator Market Size by Country (2021-2026) & (US$ Million) Table 137. Latin America Neutrophil Elastase Inhibitator Market Share by Country (2021-2026) Table 138. Latin America Neutrophil Elastase Inhibitator Market Size Forecast by Country (2027-2032) & (US$ Million) Table 139. Latin America Neutrophil Elastase Inhibitator Market Share Forecast by Country (2027-2032) Table 140. Middle East and Africa Neutrophil Elastase Inhibitator Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 141. Middle East and Africa Neutrophil Elastase Inhibitator Sales by Country (2021-2026) & (W Units) Table 142. Middle East and Africa Neutrophil Elastase Inhibitator Sales Market Share by Country (2021-2026) Table 143. Middle East and Africa Neutrophil Elastase Inhibitator Sales Forecast by Country (2027-2032) & (W Units) Table 144. Middle East and Africa Neutrophil Elastase Inhibitator Sales Market Share Forecast by Country (2027-2032) Table 145. Middle East and Africa Neutrophil Elastase Inhibitator Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 146. Middle East and Africa Neutrophil Elastase Inhibitator Market Size by Country (2021-2026) & (US$ Million) Table 147. Middle East and Africa Neutrophil Elastase Inhibitator Market Share by Country (2021-2026) Table 148. Middle East and Africa Neutrophil Elastase Inhibitator Market Size Forecast by Country (2027-2032) & (US$ Million) Table 149. Middle East and Africa Neutrophil Elastase Inhibitator Market Share Forecast by Country (2027-2032) Table 150. Key Raw Materials Table 151. Raw Materials Key Suppliers Table 152. Neutrophil Elastase Inhibitator Distributors List Table 153. Neutrophil Elastase Inhibitator Customers List Table 154. Research Programs/Design for This Report Table 155. Authors List of This Report Table 156. Secondary Sources Table 157. Primary Sources List of Figures Figure 1. Neutrophil Elastase Inhibitator Image Figure 2. Global Neutrophil Elastase Inhibitator Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neutrophil Elastase Inhibitator Market Size (2021-2032) & (US$ Million) Figure 4. Global Neutrophil Elastase Inhibitator Sales (2021-2032) & (W Units) Figure 5. Dociparstat Sodium Image Figure 6. Global Dociparstat Sodium Sales YoY Growth (2021-2032) & (W Units) Figure 7. POL-6014 Image Figure 8. Global POL-6014 Sales YoY Growth (2021-2032) & (W Units) Figure 9. KRP-109 Image Figure 10. Global KRP-109 Sales YoY Growth (2021-2032) & (W Units) Figure 11. CHF-6333 Image Figure 12. Global CHF-6333 Sales YoY Growth (2021-2032) & (W Units) Figure 13. Brevenal Image Figure 14. Global Brevenal Sales YoY Growth (2021-2032) & (W Units) Figure 15. Others Image Figure 16. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 17. Global Neutrophil Elastase Inhibitator Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Neutrophil Elastase Inhibitator Market Share by Type 2025 VS 2032 Figure 19. North America Neutrophil Elastase Inhibitator Sales Market Share in Volume by Type in 2025 Figure 20. North America Neutrophil Elastase Inhibitator Sales Market Share in Value by Type in 2025 Figure 21. Europe Neutrophil Elastase Inhibitator Sales Market Share in Volume by Type in 2025 Figure 22. Europe Neutrophil Elastase Inhibitator Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Neutrophil Elastase Inhibitator Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Neutrophil Elastase Inhibitator Sales Market Share in Value by Type in 2025 Figure 25. Latin America Neutrophil Elastase Inhibitator Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Neutrophil Elastase Inhibitator Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Neutrophil Elastase Inhibitator Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Neutrophil Elastase Inhibitator Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Neutrophil Elastase Inhibitator Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Bronchiectasis Image Figure 32. Global Bronchiectasis Sales YoY Growth (2021-2032) & (W Units) Figure 33. Acute Myelocytic Leukemia Image Figure 34. Global Acute Myelocytic Leukemia Sales YoY Growth (2021-2032) & (W Units) Figure 35. Respiratory Image Figure 36. Global Respiratory Sales YoY Growth (2021-2032) & (W Units) Figure 37. Others Image Figure 38. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 39. Global Neutrophil Elastase Inhibitator Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global Neutrophil Elastase Inhibitator Market Share by Application 2025 VS 2032 Figure 41. North America Neutrophil Elastase Inhibitator Sales Market Share in Volume by Application in 2025 Figure 42. North America Neutrophil Elastase Inhibitator Sales Market Share in Value by Application in 2025 Figure 43. Europe Neutrophil Elastase Inhibitator Sales Market Share in Volume by Application in 2025 Figure 44. Europe Neutrophil Elastase Inhibitator Sales Market Share in Value by Application in 2025 Figure 45. Asia-Pacific Neutrophil Elastase Inhibitator Sales Market Share in Volume by Application in 2025 Figure 46. Asia-Pacific Neutrophil Elastase Inhibitator Sales Market Share in Value by Application in 2025 Figure 47. Latin America Neutrophil Elastase Inhibitator Sales Market Share in Volume by Application in 2025 Figure 48. Latin America Neutrophil Elastase Inhibitator Sales Market Share in Value by Application in 2025 Figure 49. Middle East and Africa Neutrophil Elastase Inhibitator Sales Market Share in Volume by Application in 2025 Figure 50. Middle East and Africa Neutrophil Elastase Inhibitator Sales Market Share in Value by Application in 2025 Figure 51. North America Neutrophil Elastase Inhibitator Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 52. North America Neutrophil Elastase Inhibitator Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. North America Neutrophil Elastase Inhibitator Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. North America Neutrophil Elastase Inhibitator Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Neutrophil Elastase Inhibitator Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 56. Europe Neutrophil Elastase Inhibitator Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Neutrophil Elastase Inhibitator Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Europe Neutrophil Elastase Inhibitator Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Neutrophil Elastase Inhibitator Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 60. Asia-Pacific Neutrophil Elastase Inhibitator Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Neutrophil Elastase Inhibitator Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Asia-Pacific Neutrophil Elastase Inhibitator Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Neutrophil Elastase Inhibitator Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 64. Latin America Neutrophil Elastase Inhibitator Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Neutrophil Elastase Inhibitator Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Latin America Neutrophil Elastase Inhibitator Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Neutrophil Elastase Inhibitator Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 68. Middle East and Africa Neutrophil Elastase Inhibitator Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Neutrophil Elastase Inhibitator Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Middle East and Africa Neutrophil Elastase Inhibitator Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. Neutrophil Elastase Inhibitator Value Chain Figure 72. Key Raw Materials Price Figure 73. Manufacturing Cost Structure Figure 74. Neutrophil Elastase Inhibitator Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Dociparstat Sodium
  • POL-6014
  • KRP-109
  • CHF-6333
  • Brevenal
  • Others
Applications
  • Bronchiectasis
  • Acute Myelocytic Leukemia
  • Respiratory
  • Others
Companies covered
  • AstraZeneca Plc
  • Polyphor Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Chiesi Farmaceutici SpA
  • Cantex Pharmaceuticals Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neutrophil Elastase Inhibitator Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Neutrophil Elastase Inhibitator Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Neutrophil Elastase Inhibitator Market by Type
  6. 1.3.1 Dociparstat Sodium
  7. 1.3.2 POL-6014
  8. 1.3.3 KRP-109
  9. 1.3.4 CHF-6333
  10. 1.3.5 Brevenal
  11. 1.3.6 Others
  12. 1.4 Global Neutrophil Elastase Inhibitator Market Size by Type
  13. 1.4.1 Global Neutrophil Elastase Inhibitator Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Neutrophil Elastase Inhibitator Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Neutrophil Elastase Inhibitator Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Neutrophil Elastase Inhibitator Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Neutrophil Elastase Inhibitator Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Neutrophil Elastase Inhibitator Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Neutrophil Elastase Inhibitator Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Neutrophil Elastase Inhibitator Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Neutrophil Elastase Inhibitator Industry Trends
  2. 2.2 Neutrophil Elastase Inhibitator Industry Drivers
  3. 2.3 Neutrophil Elastase Inhibitator Industry Opportunities and Challenges
  4. 2.4 Neutrophil Elastase Inhibitator Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Neutrophil Elastase Inhibitator Revenue (2021-2026)
  2. 3.2 Global Top Players by Neutrophil Elastase Inhibitator Sales (2021-2026)
  3. 3.3 Global Top Players by Neutrophil Elastase Inhibitator Price (2021-2026)
  4. 3.4 Global Neutrophil Elastase Inhibitator Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Neutrophil Elastase Inhibitator Major Company Production Sites & Headquarters
  6. 3.6 Global Neutrophil Elastase Inhibitator Company, Product Type & Application
  7. 3.7 Global Neutrophil Elastase Inhibitator Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Neutrophil Elastase Inhibitator Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Neutrophil Elastase Inhibitator Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Neutrophil Elastase Inhibitator Tier 1, Tier 2, and Tier 3
4 Neutrophil Elastase Inhibitator Regional Status and Outlook
  1. 4.1 Global Neutrophil Elastase Inhibitator Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Neutrophil Elastase Inhibitator Historic Market Size by Region
  3. 4.2.1 Global Neutrophil Elastase Inhibitator Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Neutrophil Elastase Inhibitator Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Neutrophil Elastase Inhibitator Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Neutrophil Elastase Inhibitator Forecasted Market Size by Region
  7. 4.3.1 Global Neutrophil Elastase Inhibitator Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Neutrophil Elastase Inhibitator Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Neutrophil Elastase Inhibitator Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Neutrophil Elastase Inhibitator by Application
  1. 5.1 Neutrophil Elastase Inhibitator Market by Application
  2. 5.1.1 Bronchiectasis
  3. 5.1.2 Acute Myelocytic Leukemia
  4. 5.1.3 Respiratory
  5. 5.1.4 Others
  6. 5.2 Global Neutrophil Elastase Inhibitator Market Size by Application
  7. 5.2.1 Global Neutrophil Elastase Inhibitator Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Neutrophil Elastase Inhibitator Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Neutrophil Elastase Inhibitator Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Neutrophil Elastase Inhibitator Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Neutrophil Elastase Inhibitator Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Neutrophil Elastase Inhibitator Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Neutrophil Elastase Inhibitator Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Neutrophil Elastase Inhibitator Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 AstraZeneca Plc
  2. 6.1.1 AstraZeneca Plc Company Information
  3. 6.1.2 AstraZeneca Plc Business Overview
  4. 6.1.3 AstraZeneca Plc Neutrophil Elastase Inhibitator Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 AstraZeneca Plc Neutrophil Elastase Inhibitator Product Portfolio
  6. 6.1.5 AstraZeneca Plc Recent Developments
  7. 6.2 Polyphor Ltd
  8. 6.2.1 Polyphor Ltd Company Information
  9. 6.2.2 Polyphor Ltd Business Overview
  10. 6.2.3 Polyphor Ltd Neutrophil Elastase Inhibitator Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Polyphor Ltd Neutrophil Elastase Inhibitator Product Portfolio
  12. 6.2.5 Polyphor Ltd Recent Developments
  13. 6.3 Kyorin Pharmaceutical Co Ltd
  14. 6.3.1 Kyorin Pharmaceutical Co Ltd Company Information
  15. 6.3.2 Kyorin Pharmaceutical Co Ltd Business Overview
  16. 6.3.3 Kyorin Pharmaceutical Co Ltd Neutrophil Elastase Inhibitator Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Kyorin Pharmaceutical Co Ltd Neutrophil Elastase Inhibitator Product Portfolio
  18. 6.3.5 Kyorin Pharmaceutical Co Ltd Recent Developments
  19. 6.4 Chiesi Farmaceutici SpA
  20. 6.4.1 Chiesi Farmaceutici SpA Company Information
  21. 6.4.2 Chiesi Farmaceutici SpA Business Overview
  22. 6.4.3 Chiesi Farmaceutici SpA Neutrophil Elastase Inhibitator Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Chiesi Farmaceutici SpA Neutrophil Elastase Inhibitator Product Portfolio
  24. 6.4.5 Chiesi Farmaceutici SpA Recent Developments
  25. 6.5 Cantex Pharmaceuticals Inc
  26. 6.5.1 Cantex Pharmaceuticals Inc Company Information
  27. 6.5.2 Cantex Pharmaceuticals Inc Business Overview
  28. 6.5.3 Cantex Pharmaceuticals Inc Neutrophil Elastase Inhibitator Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Cantex Pharmaceuticals Inc Neutrophil Elastase Inhibitator Product Portfolio
  30. 6.5.5 Cantex Pharmaceuticals Inc Recent Developments
7 North America by Country
  1. 7.1 North America Neutrophil Elastase Inhibitator Sales by Country
  2. 7.1.1 North America Neutrophil Elastase Inhibitator Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Neutrophil Elastase Inhibitator Sales by Country (2021-2026)
  4. 7.1.3 North America Neutrophil Elastase Inhibitator Sales Forecast by Country (2027-2032)
  5. 7.2 North America Neutrophil Elastase Inhibitator Market Size by Country
  6. 7.2.1 North America Neutrophil Elastase Inhibitator Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Neutrophil Elastase Inhibitator Market Size by Country (2021-2026)
  8. 7.2.3 North America Neutrophil Elastase Inhibitator Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Neutrophil Elastase Inhibitator Sales by Country
  2. 8.1.1 Europe Neutrophil Elastase Inhibitator Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Neutrophil Elastase Inhibitator Sales by Country (2021-2026)
  4. 8.1.3 Europe Neutrophil Elastase Inhibitator Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Neutrophil Elastase Inhibitator Market Size by Country
  6. 8.2.1 Europe Neutrophil Elastase Inhibitator Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Neutrophil Elastase Inhibitator Market Size by Country (2021-2026)
  8. 8.2.3 Europe Neutrophil Elastase Inhibitator Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Neutrophil Elastase Inhibitator Sales by Country
  2. 9.1.1 Asia-Pacific Neutrophil Elastase Inhibitator Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Neutrophil Elastase Inhibitator Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Neutrophil Elastase Inhibitator Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Neutrophil Elastase Inhibitator Market Size by Country
  6. 9.2.1 Asia-Pacific Neutrophil Elastase Inhibitator Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Neutrophil Elastase Inhibitator Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Neutrophil Elastase Inhibitator Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Neutrophil Elastase Inhibitator Sales by Country
  2. 10.1.1 South America Neutrophil Elastase Inhibitator Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Neutrophil Elastase Inhibitator Sales by Country (2021-2026)
  4. 10.1.3 South America Neutrophil Elastase Inhibitator Sales Forecast by Country (2027-2032)
  5. 10.2 South America Neutrophil Elastase Inhibitator Market Size by Country
  6. 10.2.1 South America Neutrophil Elastase Inhibitator Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Neutrophil Elastase Inhibitator Market Size by Country (2021-2026)
  8. 10.2.3 South America Neutrophil Elastase Inhibitator Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Neutrophil Elastase Inhibitator Sales by Country
  2. 11.1.1 Middle East and Africa Neutrophil Elastase Inhibitator Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Neutrophil Elastase Inhibitator Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Neutrophil Elastase Inhibitator Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Neutrophil Elastase Inhibitator Market Size by Country
  6. 11.2.1 Middle East and Africa Neutrophil Elastase Inhibitator Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Neutrophil Elastase Inhibitator Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Neutrophil Elastase Inhibitator Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Neutrophil Elastase Inhibitator Value Chain Analysis
  2. 12.1.1 Neutrophil Elastase Inhibitator Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Neutrophil Elastase Inhibitator Production Mode & Process
  7. 12.2 Neutrophil Elastase Inhibitator Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Neutrophil Elastase Inhibitator Distributors
  10. 12.2.3 Neutrophil Elastase Inhibitator Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst